Table 3. Clinical characteristics of the 3 patients with imatinib-resistance.
| Patient (No) | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
| Age | 57 | 43 | 28 |
| Clinical manifestations | fatigue, weight loss, bone pain, splenomegaly | night sweats, fatigue, splenomegaly | cough, bone pain, splenomegaly |
| AEC at first diagnosis | 7×109/L | 7×109/L | 4.32×109/L |
| Initial karyotype | 47, XY, +8[12] | 46, XY[15] | 46, XY[20] |
| Dose of imatinib (mg/day) | 100→400 | 100 | 200 |
| Time to imatinib resistance (months) | primary resistance | 52.5 | 14 |
| Mutation | T674I | T674I | T674I |
| Disease phase at diagnosis of resistance | CP | CP | BP |
| Therapy following resistance | nilotinib(400 mg BID), hydroxyurea(1g BID) | imatinib(100→400 mg/day), nilotinib(400 mg BID), dasatinib(100 mg/day), cyclophosphamide/oncovin/prednisone | imatinib 400 mg/day, homoharringtonine/cytarabine |
| Follow up after resistance | death after 14 months | death after 17 months | death after 41 days |
CP: chronic phase, BP: blast phase, BID: twice a day.